This program invites applications proposing pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that aim to prevent Alzheimer’s disease (AD), slow its progression, or treat its cognitive and behavioral symptoms.
Amount: $11,325,000
Due Date: 02/05/2025